Ventana Introduces Stress-Suppressing Chewing Gum

NEW YORK, NEW YORK, Aug 14 (MARKET WIRE) --
Ventana Biotech Inc. ("Ventana") (PINK SHEETS: VNTA), a biotechnology
company developing an appetite-suppressing chewing gum, today revealed
its latest groundbreaking research in tackling yet another of the modern
lifestyle-induced illnesses: Stress!

Ventana Biotech Inc. is proud to reveal that it is conducting research in
developing a Stress Suppressing Chewing Gum that builds on its experience
with its current line of anti-obesity products. Having gained experience
with stimulating the body's own natural hormones in suppressing appetite,
Ventana has commenced similar research with the aim of suppressing stress.

A preliminary estimate of the royalty cash-flow from a successful
stress-suppressing drug is at USD 1.6 - 1.9 billion over a 10 year period.

Stress kills and disables millions of people in the world, where the
pressure for constantly adjusting to an ever-increasing plethora of
demands simply knocks people off their feet. Prolonged stress leads to a
disabling and chronic condition: Post-Traumatic Stress Syndrome (PTSS).
Until about ten years ago, this used to only affect soldiers, paramedics
and a few others who had to work under unbearable circumstances, but
recently the ratio of "ordinary office workers" getting PTSS has
increased at an alarming rate, leading to millions of people suffering
from PTSS today!

Having PTSS is a life-debilitating illness, in effect causing the victims
to be unable to handle everyday living, including having even the
simplest job, shopping, cooking, travelling, and co-existing with
children or others. And most distressing, there is no cure in the
ordinary sense. Once a person has been stressed beyond the
breaking-point, there is almost never any chance of getting back to a
normal life with a job and family. It is therefore of utmost importance
to make sure never to cross that invisible boundary between "healthy
stress" and crippling stress. Ventana's new Stress Suppressing Chewing
Gum will do just that, and prevent people from getting stressed beyond
the breaking point.

About Ventana Biotech Inc

Ventana is positioning itself as the leading bioscience company in the
development and commercial licensure of novel therapeutic anti-obesity
drug treatment. The company leverages cutting-edge research
collaborations to achieve breakthroughs in innovative anti-obesity
treatments, and then licenses these patented drug product candidates to
Big Pharmaceutical and Biotechnology companies.

FORWARD-LOOKING STATEMENTS:

Statements about Ventana's future expectations and all other statements
in this press release other than historical facts are "forward-looking
statements" within the meaning of section 27A of the Securities Act of
1933, Section 21E of the Securities Exchange Act of 1934, and as the term
is defined in the Private Litigation Reform Act of 1995. Ventana's actual
results could differ materially from expected results. Ventana does not
undertake any obligation to update forward-looking statements to reflect
subsequently occurring events or circumstances. Should events occur which
materially affect any comments made within this objective; Ventana will
appropriately inform the public.

For more information about Ventana Biotech Inc please contact
investor@ventanabiotech.com.

Contacts:
Ventana Biotech Inc
Janne Christensen
CEO
+44 7930 732 426
investor@ventanabiotech.com
www.ventanabiotech.com

Copyright 2009, Market Wire, All rights reserved.

-0-